DeutschNewstral
Article
Denver Post on 2016-08-31 01:48
Novartis wins US OK for biosimilar version of Amgen’s Enbrel
Related news
FDA Approves Novartis’s Biosimilar to Amgen’s Enbrelwsj.com- PFDA approves biosimilar of Amgen’s Enbrelpacbiztimes.com
- PFDA approves biosimilar competitor to Amgen’s Enbrelpacbiztimes.com
- PAmgen’s Humira biosimilar delayed, Enbrel approvedpacbiztimes.com
- FDA Approves Amgen’s Biosimilar Version of Humirawsj.com
- PFDA declines to approve Novartis biosimilar for Amgen’s Neulastapacbiztimes.com
- PNovartis biosimilar works as well as Amgen’s Neulastapacbiztimes.com
EC Approves Amgen’s Biosimilar Adalimumabjdsupra.com- FDA Approves Expanded Use of Amgen’s Enbrel®jdsupra.com
- Enbrel Biosimilar in Europe and USjdsupra.com
- PJudge blocks sale of competitor for Amgen’s Enbrelpacbiztimes.com
- PBiosimilar competition hurts Amgen’s top linepacbiztimes.com
- PFDA approves biosimilar of Amgen’s Neulastapacbiztimes.com
- FDA Approves Amgen’s Biosimilar of Avastin®jdsupra.com
- New Developments in AbbVie’s BPCIA Suit Targeting Amgen’s Humira® Biosimilarjdsupra.com
- PAmgen fends off biosimilar for arthritis drug Enbrelpacbiztimes.com
- PEuropeans OK expanded use of Amgen’s Blincytopacbiztimes.com
- PStudy shows Amgen’s new biosimilar cancer drug safe, effectivepacbiztimes.com
- PEuropeans recommend approval of Amgen’s biosimilar of AbbVie’s Humirapacbiztimes.com
- EMA Adopts Positive Opinion for Amgen’s Eculizumab Biosimilar Candidate BEKEMV®jdsupra.com